Key statistics
On Tuesday, Sandoz Group AG (SDZNY:QXI) closed at 45.04, -3.76% below its 52-week high of 46.80, set on Nov 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 45.61 |
---|---|
High | 46.00 |
Low | 44.97 |
Bid | -- |
Offer | -- |
Previous close | 46.20 |
Average volume | 117.59k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | 0.4956 USD |
---|---|
Annual div yield (ADY) | 1.07% |
Div ex-date | May 03 2024 |
Div pay-date | Jun 18 2024 |
Data delayed at least 15 minutes, as of Nov 12 2024 21:12 GMT.
More ▼
Announcements
- Sandoz reports third-quarter and nine-month 2024 sales
- Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
- Sandoz reports second-quarter sales and half-year 2024 results
- Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
- FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
- Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
- Sandoz reports first quarter 2024 sales
- Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
- Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
- Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
More ▼